ID   A-375 NRAS p.Q61K
AC   CVCL_JF22
SY   A-375 NRASQ61K; NRAS mutant-A375 Isogenic Cell Line
DR   ATCC; CRL-1619IG-2
DR   cancercelllines; CVCL_JF22
DR   Wikidata; Q54605989
WW   https://www.atcc.org/en/support/technical-support/faqs/isogenic-cell-line-with-ras-mutation
CC   Population: Caucasian.
CC   Characteristics: Shows significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib when compared to its parental cell line in 2D and 3D culture systems. Can be a useful model to study the RAS-RAF-MEK-ERK-MAP kinase signaling pathway and to screen potential BRAF inhibitors and anti-cancer compounds for drug discovery and development (ATCC=CRL-1619IG-2).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Homozygous; Note=By CRISPR/Cas9 (ATCC=CRL-1619IG-2).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 9
ST   D5S818: 12
ST   D7S820: 9
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 05-10-23; Version: 15
//